

# Massachusetts General Hospital Corporate & Foundation Relations Office of Development

### FOUNDATION FUNDING OPPORTUNITIES: NOV 20, 2020

Please contact Corporate & Foundation Relations in the Office of Development at <a href="mailto:devcfr@mgh.harvard.edu">devcfr@mgh.harvard.edu</a> if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than <u>15% in indirect costs (IDC)</u> will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. <u>Training fellowships</u> from foundations, public charity, and non-profit organizations <u>are excluded</u> from this minimum IDC requirement.

Have you updated your MGH Researcher profile? Go to <a href="https://researchers.mgh.harvard.edu/">https://researchers.mgh.harvard.edu/</a> today!

## 1. Discovery Grant, American Brain Tumor Association (ABTA)

The ABTA Discovery Grants are intended to encourage the development of new approaches to the diagnosis and treatment of brain tumors. By providing funding through its Discovery Grants, the ABTA seeks to support high-risk/high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care.

These grants specifically encourage novel research by allowing researchers to conduct the early scientific studies needed to secure additional/future funding for their projects. Additionally, investigators from sciences outside traditional biological fields are encouraged to apply. The development of new diagnostic and therapeutic approaches advances the understanding and treatment of brain tumors, and increases the potential for improving, extending and ultimately saving the lives of those living with a brain tumor diagnosis.

These grants seeks projects focused on all brain tumor types, benign or malignant, primary or secondary (metastatic).

Appropriate research projects include, but are not limited to, the following areas:

- Biomarkers of risk, disease burden, and/or treatment response
- Brain Tumor Biology
- Clinical research
- Diagnosis
- Drug Delivery



Do you want to learn more about identifying external funding opportunities? Please <u>click here</u> to request a research consultation with *Amy Robb* or see ECOR's website for information on the <u>Pivot</u> database.

- Etiology
- Genetics
- Imaging
- Molecular/genetic epidemiology
- Novel Therapeutics
- Risk assessment

- A Lead Mentor is required only for Applicants/PIs that are within first 5 years of a faculty appointment.
  - o Must hold a full-time faculty appointment at the A pplicant /PI 's institution
  - o Must currently conduct brain tumor research
- Co-Mentor Requirements
  - A Co-Mentor is optional for this mechanism
  - Must hold a full-time faculty appointment at a non-profit institution or organization anywhere in the world
  - o Is not required to conduct brain tumor research

Citizenship: Unrestricted

Award Amount: \$50,000 for 1 year

**Indirect Costs: None** 

LOI Deadline: December 9, 2020

(Invited) Proposal Deadline: March 24, 2021 Website: <a href="https://www.abta.org/discovery-grants/">https://www.abta.org/discovery-grants/</a>

# 2. KidneyX Redesign Dialysis Phase II, American Society of Nephrology (ASN)

The Kidney Innovation Accelerator (KidneyX) is a public-private partnership between the US Department of Health and Human Services and the American Society of Nephrology to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases. KidneyX seeks to improve the lives of the 850 million people worldwide currently affected by kidney diseases by accelerating the development of drugs, devices, biologics and other therapies across the spectrum of kidney care including prevention, diagnostics, and treatment.

Building off the success of KidneyX's inaugural prize competition, Redesign Dialysis Phase 1, Phase 2 challenges participants to build and test prototype solutions, or components of solutions, that can replicate normal kidney functions or improve dialysis access.

We are seeking prototype solutions that address any of these categories:

- Blood Filtration (filtering blood to remove waste and excess fluid)
- Electrolyte Homeostasis (maintaining appropriate levels of key minerals in the blood)
- Volume Regulation (regulating the amount of and/or removing excess fluid).

- Toxin Removal and Secretion (removing, limiting or preventing toxins in the bloodstream).
- Filtrate Drainage and Connectivity (removing excess filtrate after processing; connectivity issues for filtration, processing, and exterior drainage)
- Dialysis Access (vascular, peritoneal, blood circuit, or alternative (e.g., GI tract) access)

• You can participate and win in Phase 2 even if you didn't participate in Phase 1.

Citizenship: United States

Award Amount: \$500,000 Indirect Costs: Unspecified

Submission Deadline: January 31, 2021

Website: https://www.kidneyx.org/prizecompetitions/RedesignDialysisPhaseII

#### 3. Arthritis Research Grants, Arthritis National Research Foundation (ANRF)

All Arthritis Multiple research grants for projects across Arthritis, Rheumatology and Autoimmune Diseases.

Disease Focus Areas (including, but not limited to):

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Fibromyalgia
- Lupus
- Gout
- Scleroderma
- Osteoarthritis
- Juvenile Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Arthritis and Aging
- Autoimmune conditions with relevance to Arthritis

Citizenship: Unrestricted

Award Amount: \$100,000 for 1 year

**Indirect Costs: None** 

Application Deadline: January 17, 2021

Website: https://curearthritis.org/arthritis-research-grants/

4. Ankylosing Spondylitis Research Grant, Arthritis National Research Foundation (ANRF)

The Arthritis National Research Foundation is seeking grant applications that focus on the study of Ankylosing Spondylitis.

Eligibility requirements (partial list):

• Applicants must be newer MD and/ or PhD applicants at early stages in their career (equivalent to assistant professor/instructor/senior post-docs).

Citizenship: Unspecified

Award Amount: \$100,000 for 1 year

Indirect Costs: None

Application Deadline: January 17, 2021

Website: <a href="https://curearthritis.org/ankylosing-spondylitis-grant/">https://curearthritis.org/ankylosing-spondylitis-grant/</a>

# 5. Arthritis and the Aging Process Research Grant, Arthritis National Research Foundation (ANRF)

In a collaborative effort, the Arthritis National Research Foundation (ANRF) and the American Federation for Aging Research (AFAR) are seeking grant applications that focus on studying the underlying mechanisms of the aging process as it relates to arthritis.

The Arthritis National Research Foundation (ANRF) is seeking grant applications that focus on studying arthritis and related autoimmune diseases including but not limited to:

- osteoarthritis
- rheumatoid arthritis
- juvenile arthritis
- lupus
- psoriatic arthritis
- gout
- ankylosing spondylitis
- scleroderma
- fibromyalgia
- uveitis (shown in relationship to autoimmune forms of arthritis)

Eligibility requirements (partial list):

• Priority will be given to meritorious applications from newer M.D. and/or Ph.D. applicants in early stage career development (equivalent to assistant professor and without serving as PI on an NIH R01 award).

Citizenship: Unspecified

Award Amount: \$100,000 for 1 year

Indirect Costs: None

Application Deadline: January 17, 2021 Website: <a href="https://curearthritis.org/grants/">https://curearthritis.org/grants/</a>

#### 6. Psoriatic Arthritis Research Grant, Arthritis National Research Foundation (ANRF)

In a collaborative effort, the Arthritis National Research Foundation (ANRF) and the National Psoriasis Foundation (NPF) are seeking grant applications that focus on studying psoriatic arthritis.

The Arthritis National Research Foundation (ANRF) is seeking grant applications that focus on studying arthritis and related autoimmune diseases including but not limited to:

- osteoarthritis
- rheumatoid arthritis
- juvenile arthritis
- lupus
- psoriatic arthritis
- gout
- ankylosing spondylitis
- scleroderma
- fibromyalgia
- uveitis (shown in relationship to autoimmune forms of arthritis)

Eligibility requirements (partial list):

• Applicants must be newer MD and/ or PhD applicants at early stages in their career (equivalent to assistant professor/instructor/senior post-docs).

Citizenship: Unspecified

Award Amount: \$100,000 for 1 year

**Indirect Costs: None** 

Application Deadline: January 17, 2021

Website: <a href="https://curearthritis.org/ankylosing-spondylitis-grant/">https://curearthritis.org/ankylosing-spondylitis-grant/</a>

## 7. Research Grants, Bryon Riesch Paralysis Foundation

The goal of the Bryon Riesch Paralysis Foundation is to provide grants to fund research in the hopes of finding a cure for paralysis. The intent of these grants is to promote new and exciting research in the field of paralysis. The amount of grant money distributed is pre-determined by the Bryon Riesch Paralysis Foundation (BRPF) Board of Directors. The following areas of research are of primary interest to the Bryon Riesch Paralysis Foundation:

- Factors relating to re-myelination, axonal preservation or growth, and cell
  differentiation that may lead to acute or chronic recovery in spinal cord injured
  individuals.
- Drug therapies or other interventions that will limit secondary damage after a spinal cord injury.

 Activities that investigate underlying problems associated with neurological disorders such as spasticity, chronic pain, bladder/bowel function, or sexual function.

# Citizenship: United States

Award Amount: The grant provided is good for one-year periods and may be renewed at the discretion of the BRPF. The grant amount will be based upon availability of BRPF funds and will be determined by the Foundation.

**Indirect Costs: None** 

Application Deadline: December 21, 2020

Website: <a href="http://brpf.org/research-grant-application/">http://brpf.org/research-grant-application/</a>

# 8. Young Investigator Award (YIA), Children's Tumor Foundation (CTF)

The Young Investigator Award (YIA), CTF's longest-running competitive award program since the mid 1980s, has traditionally provided two years of funding to early-career NF researchers. The goal is to enable these trainees to become established independent investigators in NF-related fields. The YIA program has provided seed funding to attract researchers to the field and produce data to secure larger grants, such as from the NIH and CDMRP NFRP. Several former YIAs are now leaders in the NF research and clinical communities. In fact, CTF's 'seeding' of the NF field with new talent has been hailed as a key reason for rapid advancements in NF research in recent years.

The YIA mechanism supports basic and translational research towards:

- Understanding cellular, genetic, and molecular mechanisms underlying the pathogenesis of NF1, NF2, and schwannomatosis phenotypes
- Identifying and/or testing novel therapeutic targets
- Testing candidate therapeutics
- Analysis of natural history of NF

The focus of YIA research includes but is not limited to:

- NF1, NF2, and schwannomatosis
- Manifestations such as –
- Neurofibromas, schwannomas, malignant peripheral nerve sheath tumors, other brain and nervous system tumors
- Bone abnormalities
- Cardiovascular abnormalities
- Learning disorders
- Pain

## Eligibility requirements (partial list):

• Applicant must be one of the following postdoctoral fellow (MD, PhD, or equivalent) with no more than 7 years past completion of their first doctoral degree.

- Applicant must be affiliated with the laboratory of a senior researcher who is the
  applicant's research sponsor. The sponsor must offer a training environment that is
  conducive for the growth and education of an early-career NF researcher. As part of the
  application, the mentor will be asked to describe the intended training plan.
- In a given year, more than one member from a laboratory can apply for a YIA. However, only one application per laboratory per year will be funded.

Citizenship: Unrestricted

Award Amount: \$133,500- \$174,000 paid over 3 years

Indirect Costs: 10%

LOI Deadline: January 1, 2021

(Invited) Application Deadline: March 5, 2021

Website: <a href="http://www.ctf.org/research/awards-applications">http://www.ctf.org/research/awards-applications</a>

## 9. Research Fellowships, Cooley's Anemia Foundation

The Cooley's Anemia Foundation invites national and international clinical and basic science investigators (postdoctoral or junior faculty) to apply for its prestigious fellowship program. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. The areas of interest include, but are not limited to, studies of globin gene regulation, globin gene transfer and expression, fetal hemoglobin production, hematopoietic stem cell research, bone marrow transplantation, iron chelation and iron overload, endocrine and cardiac disorders in thalassemia, and transfusion therapy and its complications.

#### Eligibility requirements (partial list):

- Postdoctoral applicants must have adequate preceptorship and guidance by an experienced investigator. The sponsor of a postdoctoral fellow should be an investigator with adequate experience and at an institution with adequate research facilities.
- Postdoctoral applicants must have an MD, PhD, or equivalent degree, and cannot hold a faculty position.
- Junior faculty applicants must have an MD, PhD, or equivalent degree, and must have completed less than five years at the assistant professor level at the time the applications are due. Junior faculty members do not require sponsors.
- Preference will be given to applicants who have not yet achieved R-01 funding from the NIH.

Citizenship: Unrestricted

Award Amount: \$100,000 paid over 2 years

**Indirect Costs: 10%** 

Application Deadline: February 1, 2021

Website: <a href="https://www.thalassemia.org/caf-accepting-applications-for-2021-medical-research-grants-fellowships-until-feb-1-2021/">https://www.thalassemia.org/caf-accepting-applications-for-2021-medical-research-grants-fellowships-until-feb-1-2021/</a>

**10.** Support for Ongoing Clinical Research in Thalassemia, Cooley's Anemia Foundation The Cooley's Anemia Foundation invites national and international applicants to apply for grants to support ongoing clinical research projects in thalassemia.

The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the following areas impacting patients with thalassemia, including but not limited to: cardiac issues and iron overload; fertility, pregnancy and family planning; quality of life, psycho-social impact and/or burden of disease.

# Eligibility requirements (partial list):

• Junior and senior faculty are eligible; fellows and trainees are not eligible.

Citizenship: Unrestricted

Award Amount: \$50,000 for 1 year

**Indirect Costs: 10%** 

LOI Deadline: December 21, 2020 Application Deadline: February 1, 2021

Website: https://www.thalassemia.org/caf-accepting-applications-for-2021-medical-research-

grants-fellowships-until-feb-1-2021/

#### 11. Translational Adult Glioma Grant Award, Ivy Foundation

The Ben & Catherine Ivy Foundation Emerging Adult Glioma Award provides grant support to investigators conducting high-impact, high-reward translational research for glioma. This award is intended to support projects designed to contribute to identifying therapies that will impact the survival of patients with brain cancer.

Citizenship: Unrestricted

Award Amount: \$600,000 paid over 2 years Indirect Costs: 10% (included in award total)

Application Deadline: March 1, 2021

Website: <a href="http://ivyfoundation.org/ivy-foundation-translational-adult-glioma-grant-award/">http://ivyfoundation.org/ivy-foundation-translational-adult-glioma-grant-award/</a>

# 12. OREF Etiology of Hip Osteoarthritis Grant in Honor of William H. Harris, MD, Orthopaedic Research and Education Foundation (OREF) NEW!

OREF's Etiology of Hip Osteoarthritis Grant in Honor of William H. Harris, MD:

• Provides funding to investigator-initiated research proposals focused on the etiology of hip osteoarthritis.

- Encourages the deployment of innovative approaches and frameworks to delineate the etiopathogenesis of this common condition.
- Includes the use of various -omics platforms, national//international data bases, artificial intelligence/machine learning, and novel imaging modalities

- Orthopaedic Surgeon as PI or co-investigator.
- Must be licensed to practice and working in an institution in the U.S.
- A PhD or DVM may serve as the principal investigator but must hold a faculty appointment in an orthopaedic department in the U.S. and an orthopaedic surgeon must serve as a co-investigator.

Citizenship: United States

Award Amount: \$250,000 paid over 2 years

**Indirect Costs: None** 

LOI Deadline: December 10, 2020

(Invited) Application Deadline: February 21, 2021

Website: https://www.oref.org/grants-and-awards/grant-programs/research-specific-

grants/harris-grant

# 13. OREF Injectable Orthobiologics of Knee Osteoarthritis Grant in Collaboration with AAOS, Orthopaedic Research and Education Foundation (OREF) NEW!

OREF's Injectable Orthobiologics Knee Osteoarthritis Research Grant is

- Soliciting investigator-initiated research proposals focused on the broad area of
  injectable orthobiologics for the treatment of knee osteoarthritis, including but not
  limited to the following areas:
  - Determining clinical efficacy and safety of an injectable orthobiologic treatment(s) to provide decreased pain and improved function, preferably through the assessment of a balanced outcome scorecard measuring patientreported outcomes and appropriate clinical outcomes.
  - Assessing the mechanisms of action of an injectable orthobiologic treatment(s) in knee osteoarthritis to reduce pain and improve function or modify the progression of disease in patients with knee osteoarthritis.

Areas of research focus may include translational preclinical or clinical research to preferably include pilot human studies.

#### Eligibility requirements (partial list):

- Orthopaedic Surgeons licensed to practice in the U.S and working in an institution in the U.S. with active clinical practice.
- Principal Investigator is required to be a member of the American Academy of Orthopaedic Surgeons (AAOS).

• PhDs, DVMs or other qualified researchers can serve as a co-investigator, but should hold a faculty appointment in an orthopaedic department at an institution in the U.S.

Citizenship: United States

Award Amount: \$50,000 for 1 year

Indirect Costs: None

Application Deadline: February 21, 2021

Website: <a href="https://www.oref.org/grants-and-awards/grant-programs/research-specific-">https://www.oref.org/grants-and-awards/grant-programs/research-specific-</a>

grants/injectable-orthobiologics-knee-oa

# 14. OREF Treatment of Osteoarthritis Research Grant funded by the Arthritis Foundation, Orthopaedic Research and Education Foundation (OREF) NEW!

This initiative addresses the need to support and facilitate research that can be completed within a limited time frame and budget. Competitive proposals should aim to help us better understand how to prevent and treat osteoarthritis, one of the most common causes of disability in adults.

Eligibility requirements (partial list):

- Multidisciplinary research activity is always encouraged.
- A PhD or DVM may serve as the principal investigator (PI) if s/he has a primary or secondary faculty appointment in an orthopaedic department. A letter from the department chair confirming this appointment is required.
- The orthopaedic surgeon must be licensed to practice in the United States.

Citizenship: United States

Award Amount: \$50,000 for 1 year

**Indirect Costs: None** 

LOI Deadline: December 10, 2020

(Invited) Application Deadline: February 21, 2021

Website: https://www.oref.org/grants-and-awards/grant-programs/research-specific-

grants/oref-osteoarthritis-treatment

## 15. OTA Member Full Research Grant, Orthopaedic Trauma Association (OTA)

The following grants are available for any research issue related to musculoskeletal trauma (excluding product development):

- Clinical Research Grants
- Basic Research Grants
- Directed Topic Research Grant in the following topics:
  - o Indications, utilization, and safety of local antibiotic delivery in orthopaedic trauma care
  - o Systemic and healing responses to musculoskeletal trauma in the elderly

 Tissue (bone, muscle, tendon, ligament, cartilage) regeneration and repair after musculoskeletal trauma

Citizenship: Unrestricted

#### Award Amount:

Basic Research Grants: \$50,000 paid over 2 years
Clinical Research Grants: \$80,000 paid over 2 years

• Directed Topic Research Grant: \$80,000 paid over 2 years

Indirect Costs: Unspecified

Application Deadline: January 11, 2021

Website: https://ota.org/research/grants/ota-member-full-research-grant

# 16. Health Data for Action (Data Access Award), Robert Wood Johnson Foundation (RWJF) NEW! COVID!

HD4A aims to reduce the barriers often faced in accessing rich data by serving as a conduit between data owners and interested researchers. Through this HD4A call for proposals (CFP), RWJF will make valuable data from unique data owners available to researchers.

The purpose of the 2020 HD4A CFP is primarily to award data access at no cost from one of eight anticipated data providers to successful applicants. Most selected projects will not receive a financial award for personnel or other project-related costs. However, limited funding up to \$100,000 per project is available for a small number of projects from principal investigators who have not previously received external research funding.

The HD4A program will support innovative research that uses the available data to answer important research questions. Applicants under this CFP will write a proposal for a research study using data from one of the following anticipated data providers including: athenahealth; CareJourney VRDC T-MSIS Research Collaborative; the Center for Improving Value in Health Care (CIVHC); Geisinger; the Health Care Cost Institute (HCCI); HealthShare Exchange (HSX); OCHIN ADVANCE Collaborative; and TransUnion.

Eligible research projects can focus on a variety of topics, including health care utilization and spending; benefit design; quality of care; prescribing patterns and medication adherence; chronic disease; maternal and child care; complex conditions; employer-sponsored insurance; public and private insurance; consolidation; integration, and market competition; social determinants of health and disparities; COVID-19 patient characteristics and outcomes; financial distress; mental health; housing instability; opioid use and treatment; and geographic variation in health.

Award Amount: \$100,000 for 1 year

Indirect Costs: 12%

Preliminary Proposal Deadline: December 17, 2020

(Invited) Full Proposal Deadline: April 15, 2021

Website: https://www.rwjf.org/en/library/funding-opportunities/2020/health-data-for-action-

data-access-award.html

# 17. Clinical Investigator Award, Society of Surgical Oncology (SSO)

The purpose of this award is to promote patient-oriented research conducted by surgical oncologists in clinical and translational science.

The Foundation requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus. Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group.

Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers.

Eligibility requirements (partial list):

- Applicants must be surgical oncologists within 8 years of completion of training and full SSO members for at least 6 months prior to application submission to be eligible for the award.
- Ideal applicants will be early to mid-career investigators with a track record of peerreviewed research funding who are seeking additional extramural support to further clinical cancer research.

Citizenship: Unrestricted

Award Amount: \$100,000 paid over 2 years

**Indirect Costs: None** 

Application Deadline: January 12, 2021

Website: <a href="https://www.surgonc.org/resources/clinical-investigator-award/">https://www.surgonc.org/resources/clinical-investigator-award/</a>

# 18. HTRS/Novo Nordisk Clinical Fellowship Award (CFA) in Hemophilia and Rare Bleeding Disorders, Thrombosis & Hemostasis Societies of North America

HTRS and Novo Nordisk Inc. (Novo) announce the availability of one Clinical Fellowship Award (CFA) focused on hemophilia and rare bleeding disorders for one academic year (July 1 - June 30). This award is supported by an educational grant from Novo Nordisk Inc. During the fellowship year, the awardee must be mentored by an experienced MD, MD/PhD or DO working in hemophilia or rare bleeding disorders at an established U.S.-based hemostasis treatment center (HTC).

- Applicants must be adult or pediatric hematology/oncology MDs or DOs working in the United States who will have completed a fellowship from an accredited U.S. Hematology, Hematology/Oncology, or Pediatric Hematology/Oncology training program by July 1.
- Applicants may be up to 3-years post-fellowship as of July 1 as long as the CFA grant
  provides an opportunity to focus on building a career in hemostasis for applicants who
  did not immediately pursue this career track following the completion of their
  fellowship. (CFA grants are not intended for applicants up to 3-years post-fellowship
  who have already secured a junior faculty position in hemostasis or have already
  completed an additional year in a clinical coagulation fellowship after their accredited
  hematology/oncology training program fellowship.)

# Citizenship: United States

#### Award Amount:

- \$80,000 for 1 year to support salary/fringe benefits for the applicant working in hemophilia and RBDs
- \$39,600 to support salary/fringe benefits for the primary mentor at the U.S.-based HTC identified in the applicant's proposal.

**Indirect Costs: None** 

Proposal Deadline: December 15, 2020

Website: <a href="http://www.htrs.org/HTRS/Grants-Awards/Clinical-Fellowship-Awards">http://www.htrs.org/HTRS/Grants-Awards/Clinical-Fellowship-Awards</a>